Trou­bled Te­va turns to risk-shar­ing team at Nu­ve­lu­tion to gam­ble on a new PhI­II study

When Nu­ve­lu­tion de­buted a cou­ple of years ago, the San Fran­cis­co-based de­vel­op­er with its pow­er­house board of di­rec­tors set out to pur­sue a new set of risk-shar­ing R&D deals with bio­phar­ma. To­day, it went pub­lic with one of those pacts, sign­ing off on a com­mit­ment to gam­ble on a Phase III study of Te­va’s new­ly ap­proved drug Auste­do for Tourette syn­drome, with a shot at bag­ging a re­ward if all works ac­cord­ing to plan.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER